Neion Bio, Inc.

Based in New York, Neion Bio, Inc. specializes in the biomanufacturing of biological molecules, utilizing advanced genetic engineering and stem cell technology to produce therapeutic proteins. Founded in 2024 in New York, Neion Bio, Inc. focuses on biomanufacturing biological molecules using its proprietary platform.

The company has raised USD 11. 00 mn in Seed funding led by Caffeinated Capital, alongside investors Basis Set and Haystack VC. As of March 27, 2026, this was the company's only funding deal. Neion Bio specializes in the biomanufacturing of biological molecules, producing monoclonal antibodies, enzymes, fusion proteins, peptides, and cytokines.

Their Raptor™ platform re-engineers eggs to create efficient protein factories, transforming basic inputs into complex therapeutic proteins. Their target market includes clients in the biopharmaceutical sector across North America, Europe, and select regions in Asia. The company generates revenue through collaborations with biopharmaceutical companies, providing B2B services that enable clients to manufacture biological molecules at scale. Neion Bio’s offerings allow clients to access lower-cost production through their Raptor™ platform, facilitating reliable supply chains for both therapeutic and non-therapeutic applications.

Neion Bio plans to leverage its recent Seed funding of USD 11. 00 mn to enhance its Raptor™ platform and develop new products aimed at the biopharmaceutical sector. The company targets expansion into European and Asian markets by the end of 2026, focusing on increasing capacity and efficiency in production to meet rising global demand.